Table 1 Data extraction elements

General data extraction elements

 • Study number

 • First author

 • Publication year

 • Country

 • Funding source

 • Study design

 • Polyp staging score used

 • Inclusion criteria

 • Exclusion criteria

 • Subjects (total (n), men (n), women (n))

 • Age (mean, median, range)

 • Number excluded

 • Study duration

Data extraction elements for the treatment (anti-IgE) and placebo arms

 • Subjects (total n, subjects with sinusitis and polyps (n), subjects with sinusitis without polyps (n), men (n), women (n), % subjects with asthma, % subjects with history of immunotherapy, subjects with allergy (n, %), number of dropouts/withdrawals from study)

 • Age (mean, median, range)

 • BMI (mean, median, range)

 • Disease severity

 • Concurrent medications

 • Comorbid conditions

 • Dosing regimen, dose amount, duration, frequency

 • Pre-CT score ± SD, post-CT score ± SD, length of follow-up, sample size

 • Pre-clinical polyp score ± SD, post-clinical polyp score ± SD, length of follow-up, sample size

 • Pre-quality of life instrument (SF-36, AQLQ, RSOM-31, TNSS, SNOT-20) ± SD, post-quality of life instrument (SF-36, AQLQ, RSOM-31, TNSS, SNOT-20) ± SD, length of follow-up, sample size

 • Pre-cellular inflammation (eosinophil count) ± SD, post-cellular inflammation (eosinophil count) ± SD, length of follow-up, sample size

 • Pre-nasal airflow (PNIF) ± SD, post-nasal airflow (PNIF) ± SD, length of follow-up, sample size

 • Pre-olfaction (UPSIT) ± SD, post-olfaction (UPSIT) ± SD, length of follow-up, sample size

 • Pre-systemic IgE levels ± SD, post-systemic IgE levels ± SD, length of follow-up, sample size

 • Pre-spirometric result ± SD, post-spirometric result ± SD, length of follow-up, sample size

 • List of adverse events